Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/1b Dose Escalation and Cohort Expansion Study of MGC018 in Combination With Checkpoint Inhibitor in Participants With Advanced Solid Tumors

NCT05293496 is registered in ClinicalTrials.gov with MacroGenics as lead sponsor.

NCT NCT05293496
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05293496 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/1b Dose Escalation and Cohort Expansion Study of MGC018 in Combination With Checkpoint Inhibitor in Participants With Advanced Solid Tumors
Lead sponsor
MacroGenics
Phase
Phase 1
Overall status
Completed
Start date
April 19, 2022
Completion date
August 26, 2025
Enrollment
31 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumor, castration-resistant prostatic cancer, epithelial ovarian cancer, hepatocellular cancer, malignant melanoma, pancreatic ductal carcinoma, renal cell carcinoma